Dual GLP-1 / glucagon agonist developed primarily for the Asian market.
Typical dose range: 1.5–9 mg
Frequency: Weekly
Route: Subcutaneous
Half-life: ~5 days
Evidence level: Phase 3
Innovent's candidate, structurally derived from oxyntomodulin. Strong appetite suppression with comparable GI tolerability to semaglutide.